ArticleFrontiers in pediatrics2026
Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Standard treatments for pediatric acute gastroenteritis (AGE) have critical limitations in symptom control and medication adherence among young children. This study evaluated the efficacy and safety of Erxiekang Emplastra as adjunctive therapy for AGE in children aged 1 to 14 years. Methods: This single-center retrospective cohort study reviewed electronic medical records of children hospitalized with AGE between January 2024 and March 2025. Eligible patients were categorized into an exposed group receiving Erxiekang Emplastra plus standard therapy and an unexposed group receiving standard therapy alone. The primary outcome was diarrhea duration; secondary outcomes included the 3-day Modified Vesikari Scale (MVS) and treatment-related adverse events. Multivariable linear regression was conducted to quantify the independent therapeutic benefits of the Erxiekang Emplastra. Results: A total of 1,089 eligible patients were included, with 417 in the exposed group and 672 in the unexposed group. The exposed group had significantly shorter diarrhea duration (3.83 vs. 4.92 days, Conclusion: Erxiekang Emplastra showed favorable tolerability in this pediatric AGE cohort, and its adjunctive use was independently associated with shortened diarrhea duration and reduced disease severity. Large-scale, multicenter, prospective randomized controlled trials are warranted to confirm the efficacy and safety of this intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.